论文部分内容阅读
流感疫苗是目前应对流感最有效的措施，传统疫苗包括全病毒灭活疫苗、裂解疫苗和减毒活疫苗，近年来逐渐成为研发趋势的有重组亚单位疫苗、核酸疫苗、活病毒载体疫苗等。病毒样颗粒(virus-like particle，VLP)疫苗作为特殊形式的亚单位疫苗，具有生产迅速、安全性高、免疫原性较高等优势。VLP可以高效地诱发体液免疫与细胞免疫，且可经多种途径接种。目前已有多种表达系统用于制备VLP，其中应用最为广泛的是杆状病毒表达系统。此文综述了流感病毒VLP的类型、组装、抗原选择、免疫途径以及流感病毒VLP疫苗在杆状病毒表达系统中的研究进展。“,”Currently, vaccine is the most effective measure to control influenza. Traditional vaccines include whole inactivated virus vaccine, split vaccine and live attenuated vaccine. In recent years, new influenza vaccines have gradually become a new research and development trend, including recombinant subunit vaccine, nucleic acid based vaccine and live virus vector vaccine. As a special form of subunit vaccine, virus-like particle (VLP) vaccine has the advantages of rapid production, good safety, and high immunogenicity. VLPs can efficiently induce humoral and cellular immunity, and can be immunized through multiple routes. A variety of expression systems are used in the preparation of VLPs, among which the most widely used is baculovirus expression system. This article reviews the types, assembly, antigen selection, immune pathways, and research progress of influenza virus VLP vaccines in baculovirus expression system.